The Johnson & Johnson (NYSE:JNJ) is going down by -0.16% in today’s trading session, a fall equivalent to -0.23% of the stock’s price from yesterday’s market close. A news came out 3 min ago stating that Top stock picks for 2020: The best of the biggest by MARKETWATCH. The lowest point that the shares touched during the trading session was $140.0601, while the peak of the day was recorded at a share price of $140.81. JNJ finished the previous session at $140.50 according to the data provided by Barchart, while the trading volume was observed to be $1566483.
In the 100 days of trading, JNJ managed to top a 131.72% Moving average. Additionally, Johnson & Johnson shares have achieved a 52-week range between 121.00 and 148.59 alongside 100 days raw stochastic set at 92.70%.
The number of shares outstanding, according to the fundamentals of the company, is set at 2.64B, equal to the value of $370.25B in market capitalization. In the last 30 days, Johnson & Johnson shares went down by -0.80%, adding 141.58 to growth in value, on top of a +7.92% boost since 11/08/19.
Johnson & Johnson (NYSE:JNJ) Analyst’s Estimates
Johnson & Johnson (JNJ) could record at least $1.87 per share in quarterly earnings in the upcoming report on 01/28/2020, a number that would actually represent an increase of 9.09 YOY.
According to the average analyst rating, Johnson & Johnson would be rated as Overweight. Out of 19 different analysts monitoring JNJ stock, 9 analysts rate the stock as a BUY, 8 suggest to give the rating of HOLD, 2 indicate that JNJ is an OVERWEIGHT, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.
On November 20, 2019, the stock earned a Initiated rating due to a new analyst call from Cantor Fitzgerald, while analysts from Atlantic Equities believe that the stock is set at Neutral from Underweight, as concluded on October 16, 2019. Bernstein, is still rather wary about the stock, deciding to keep the rating at Outperform as confirmed through a call on October 11, 2019.
Regardless of the rating, Credit Suisse did increase their price to $156 as they are considering target share price analysis. Goldman, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on May 28, 2019, giving the stock a Buy rating.
JNJ Key Ratios To Watch:
Taking in account the profitability of the Company, gross profit margin of +66.66% has been attained, while the operating margin has been recorded at +26.07%. The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at 9.86%. Beta value of the stock is recorded at 0.70. Additionally, Johnson & Johnson is recording price volatility of 1.11% for the period of the last seven days and 1.26% in the last 30 days.
Johnson & Johnson (NYSE:JNJ) Technical Outlook
For the period of the last 50 days, Johnson & Johnson had its Raw Stochastic average set at 92.70% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 90.12%. Stochastic %K for Johnson & Johnson, with the last 20 days included, was set at 90.06%, having Stochastic %D topping 92.48%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be encouraging for Johnson & Johnson stocks with recording 8.87% in metrics.
Johnson & Johnson Insider Watch:
Similarly, 69.27% of the company’s float is held by institutions – and there are 3,452 institutions in total holding shares of this company. The top three institutional holders of JNJ stocks are: Vanguard Group, Inc. (The) with ownership of $29.24 billion, which is approximately 226032574 of the company’s shares; Blackrock Inc., holding 188630113 shares of the stock with an approximate value of $24.4 billion; and State Street Corporation, currently with more than 151529786 shares of the company valued at $19.6 billion. Positions in Johnson & Johnson stocks held by institutional investors has been changing actively in the past six months, a period during which there were 1 insider purchases amounting to 3000 shares.